Holen Sie sich die Stockscreener-App
14.44
0.35%
0.05
Handel nachbörslich:
14.57
0.13
+0.90%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.39
Offen:
$14.29
24-Stunden-Volumen:
1.09M
Relative Volume:
0.56
Marktkapitalisierung:
$12.05B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
21.98
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
+7.76%
1M Leistung:
+7.44%
6M Leistung:
+1.91%
1J Leistung:
+4.18%
1-Tages-Spanne:
$14.27
$14.46
1-Wochen-Bereich:
$13.40
$14.46
52-Wochen-Spanne:
$12.26
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.44 | 11.15B | 3.85B | 667.93M | 142.30M | 0.657 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol
Asian Equities Climb Despite Weekly Losses - Finimize
Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks
Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX
Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains
Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com
Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol
Validea's Top Health Care Stocks Based On Peter Lynch5/5/2025 - Nasdaq
Asian ADRs See Mixed Results Despite Weekly Gains - Finimize
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Investing in Dr. Reddy’s Laboratories Ltd. ADR (RDY): What You Must Know - knoxdaily.com
LLY Stock Quote Price and Forecast - CNN
NVO Stock Quote Price and Forecast - CNN
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Asian ADRs Climb, Showcasing North And South Asia Performances - Finimize
PDD Holdings Stock Delivers Phenomenal 5.82% Surge to $95.77 on April 14 – Bullish Momentum Lifts Chinese Tech - Hindustan Herald
3 Generic Drug Stocks To Watch Amid Trade War Jitters & Inflation Woes - Barchart.com
Stocks to buy in 2025: Uno Minda, Dr Reddy’s Laboratories among top picks that could give 10-50% return - The Economic Times
Asian ADRs Shine As Zai Lab And CNFinance Lead The Gains - Finimize
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA - MarketBeat
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - TradingView
Mixed Performance For Asian Stocks Traded On US Markets - Finimize
Vanguard Group Inc. Purchases 3,911,404 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) - Defense World
Asian Equities Traded in the US as American Depositary Receipts Tumble in Thursday Trading - TradingView
Pinpoint Asset Management Ltd Acquires 473,000 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr Reddy's Slapped Rs 2,395 Cr Income Tax Notice, Pharma Giant Denies Allegations - Medical Dialogues
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Monday Trading - TradingView
Stocks to watch, April 7: IT, pharma, metals, oil-sensitive stocks, Nykaa, Dr Reddy's, Delhivery, Trent Ltd, and more - Upstox
Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority - Moneycontrol
TCS, Dr Reddy's Labs among 6 large and mid-cap stocks that hit 52-week lows on Friday - The Economic Times
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
Sensex Today | Stock Market Highlights: Sensex falls 322 points, Nifty slips 82 points as IT drags - CNBC TV18
Asian Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading - TradingView
Generics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High - Morningstar
US Tariffs on Pharma: Zydus, Dr Reddy’s at highest risk, says Jefferies; Check impact on other Indian pharma stocks - Mint
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by GQG Partners LLC - MarketBeat
American Healthcare REIT Inc (AHR) Stock: A Year of Decreases and Increases - The InvestChronicle
Asian Equities Traded in the US as ADRs Rise in Tuesday Trading - MSN
Top Indian ADRs by Market Cap: HDFC Bank, ICICI Bank & More - INDmoney
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):